Zimbabwe has rejected a major US healthcare agreement worth 367 million US dollars (272 million pounds) over five years because of Washington's request for sensitive biological samples.
This rejection was revealed after a government memo dated December was leaked, which showed Head of State Emmerson Mnangagwa believed the agreement was "lopsided".
A government spokesman has since stated that the United States was requesting genetic material for scientific study and profit but refused to share the benefits from any future vaccines.
"We will now turn to the challenging and unfortunate process of scaling back our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy said the United States had provided more than $1.9bn as health assistance to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has called for continued negotiations to find a agreement suitable to all parties so the nation's critical HIV programme can continue.
Wider Context
Zimbabwe's decision follows a similar situation in neighbouring Kenya, where a court blocked a related deal with the US following concerns were filed about the security of Kenyans' health data.
Since returning to the presidency last year, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
The agency had managed assistance for the US government, but Trump claimed its spending was "wasteful" and his administration was seeking government-to-government deals to boost transparency and responsibility.
Based on reports, Sixteen African countries have so far signed similar health pacts, constituting over $18.3bn in committed funds.
Details of the Declined Deal
The money for Zimbabwe would have supported "combating HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this collaboration would have delivered significant advantages for the people of Zimbabwe, particularly the 1.2 million currently receiving HIV treatment via US-supported initiatives," the Ambassador added.
However, official spokesman Nick Mangwana argued the arrangement was "asymmetrical".
"Our nation was requested to share its genetic material and health information over an extended period, with no equivalent assurance of benefiting from any scientific breakthroughs – such as new medicines or tests – that could result from that provided information," his statement read.
"Put simply, our country would supply the raw materials for medical research without any assurance that the end products would be accessible to our population if a future health crisis emerge."
National Interest and International Frameworks
He also noted that the US's withdrawal from the global health body and its push of bilateral health agreements were upending frameworks already set up via the international organization.
Mangwana cited its Pandemic Benefit-Sharing framework designed to manage potential pandemics.
"This system is designed to guarantee that when a nation provides its samples, the resulting advantages – including medicines and cures – are shared equitably, not commercialised exclusively by those with the funds to develop them."
These objections over the US deal "should not be misconstrued as anti-American sentiment," he added.
"We welcome ongoing discussions with our American counterparts on how future collaboration might be arranged in a manner that respects the independence and interests of each country."
Medical Community Reaction
Medical experts said it acknowledged the official position, but recommended that talks must proceed given that a large portion of the nation's Aids initiatives relied on international support.
"If specific concerns arise, including those relating to information security or implementation frameworks, these can frequently be resolved via detailed discussion and mutually agreed protections," the group commented.
The halted deal highlights the continuing debate between accepting much-needed foreign assistance and protecting local interests in an increasingly interconnected world.